Abstract Background Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC), Crohn’s disease (CD), and IBD unclassified (IBDU), affects over 7 million people worldwide. While incidence has plateaued in higher-income countries, it continues to rise in lower- and middle-income regions, including Latin America. Data from northern Central America remain scarce. Aim To characterize the clinical and phenotypic profile of IBD in Honduras, El Salvador, and Guatemala. Methods The Inflammatory Bowel Disease in Northern Central America Research and Epidemiological Study (IBD-NCARES) was a multinational, multicenter descriptive study spanning 15 years. Cases were identified using ICD-10 codes and confirmed by chart review. Sociodemographic, behavioral, and clinical variables were collected. Results Among 277 patients, UC was the predominant subtype (57.8%), highest in Honduras (71.4%). CD accounted for 11.9% of cases, with greater frequency in Honduras (25.7%). IBDU was frequent in El Salvador (40.3%) and Guatemala (38.2%) compared with Honduras (2.9%). Delayed diagnosis (>1 year) occurred in 35% of UC and 60.6% of CD patients. Complicated CD was observed in 54.5% (B2 30.3%; B3 24.2%). Extraintestinal manifestations included vascular (18.2%) and hepatic/pancreatic (9.1%) complications. Most patients received 5-aminosalicylates or systemic steroids. Only 5.1% of the overall cohort received advanced therapies. Conclusion This first multinational study of IBD in northern Central America highlights UC predominance, high rates of IBDU (likely inflated by incomplete diagnostics), frequent diagnostic delay, and limited use of advanced therapies. These findings underscore the need for regional registries, improved diagnostic capacity, and expanded therapeutic resources.
Traumatic brain injury (TBI) is still a leading cause of death and disability worldwide, with a disproportionate burden in low- and middle-income countries (LMICs) where access to imaging, invasive intracranial pressure (ICP) monitoring, and neurosurgical care is limited. This review examines recent advances in TBI management in austere environments, where standard high-resource paradigms are frequently impractical, and analyzes the quality of evidence supporting context-adapted approaches. Recent literature highlights the growing role of protocolized care pathways, noninvasive neuromonitoring adjuncts such as optic nerve sheath diameter ultrasonography, quantitative pupillometry, transcranial Doppler, and selected serum biomarkers, as well as alternative surgical strategies including hinge craniectomy. Emerging physiological frameworks, including stage-based models of intracranial decompensation, offer structured decision-making support when numeric ICP thresholds are unavailable. However, most supporting evidence remains observational, heterogeneous, and frequently extrapolated from high-income settings, with major limitations in external validation and implementation science. Enhancing outcomes in austere TBI care will depend less on technological development than on rigorous implementation science, context-specific validation, and sustainable health system strengthening to bridge the gap between evidence and clinical delivery.
Between 10 and 20% of cervical cancers are adenocarcinomas with poorer five-year survival and higher recurrence. To identify somatic alterations driving cervical cancer, we performed whole-exome sequencing of 308 subjects with invasive disease from Guatemala and Venezuela. Consistent with other studies, there is a higher rate of TP53 mutations in adenocarcinomas versus squamous cell carcinomas (SCC), especially in HPV-negative tumors. We identified a higher rate of mutations and deletions (23%) in the STK11 tumor suppressor gene in adenocarcinomas versus SCC. This result was confirmed in the AACR Project Genie and Caris cohorts. Whole-genome sequencing and SNP-array data identified significant numbers of focal deletions on chr19p that disrupt STK11, undetected by exome sequencing. In one tumor, HPV integration disrupts STK11. Chr19p is commonly deleted in cervical cancer, and we document a high rate of independent inversions, chromosomal translocations, and breakage-fusion-bridge events that provide the second hit to STK11. Significantly, STK11 alterations are associated with a younger age of onset and poorer overall survival and survival on immunotherapy. Apart from STK11, PIK3CA mutations and YAP1 amplification are prevalent cervical cancer drivers. STK11 mutations and deletions co-occur significantly with YAP1 amplifications, suggesting an interaction between these pathways. In contrast, STK11 alterations are mutually exclusive to PIK3CA mutation, suggesting redundancy. Cervical adenocarcinomas exhibit significantly lower CD274 (PD-L1) expression and a poorer response to immune checkpoint inhibitors (ICIs). STK11 mutations are associated with poor responses to ICI in other cancers, and elucidating the role of STK11 in cervical cancer may improve targeted and immunotherapies.